Purchase Order HHSN269201600341P

<p>The NIH Clinical Center awarded a purchase order to Stemcell Technologies Inc. valued at $28,950.76 on March 25, 2020, for advanced biological research products and laboratory supplies. Work is performed in Bethesda, Maryland. The order carried firm fixed-price pricing with an ultimate completion date of April 30, 2020. No set-aside was used.</p>

<p>The NIH Clinical Center awarded a purchase order to Stemcell Technologies Inc. valued at $28,950.76 on March 24, 2020, with ultimate completion on April 24, 2020. Performance takes place in Bethesda, Maryland. The order is for advanced biological research products and laboratory supplies, including cell isolation kits, cell culture media, cell separation systems, and research-grade reagents to support biomedical research. No small business set-aside was used.</p>

<p>The NIH Clinical Center awarded a purchase order to Stemcell Technologies Inc. for $29,158.30 on December 14, 2018, with completion by December 13, 2019. Performance occurs in Bethesda, Maryland. The order procures specialized biological research materials and related supplies on a firm fixed-price basis under full-and-open competition. The originating pre-solicitation posted November 23, 2018, with a due date of December 3, 2018.</p>

<p>The NIH Clinical Center awarded a purchase order to Stemcell Technologies Inc. on June 6, 2019, with a ceiling value of $13,577.40 and an ultimate completion date of July 12, 2019. The order is firm fixed price with no set-aside designation. Place of performance is Afghanistan. The source does not disclose the specific goods or services procured under this order.</p>

The NIH Clinical Center awarded a purchase order to Stemcell Technologies Inc. for $27,083.10 on December 8, 2017, with an ultimate completion date of September 19, 2019. No set-aside was used. Place of performance is Bethesda, Maryland. The order procures specialized biological research materials and cell isolation supplies from Stemcell Technologies' commercial product portfolio, including cell isolation kits, cell culture media, and associated consumables for research applications at the...

<p>The National Institutes of Health Clinical Center awarded a purchase order to Stemcell Technologies Inc. valued at $25,213.10 on January 2, 2013, for specialized biological research materials. Place of performance is Bethesda, Maryland. The order closed on January 2, 2013, under firm fixed price terms with no small business set-aside.</p>

<p>The NIH Clinical Center awarded a purchase order to Stemcell Technologies Inc. for cell therapeutic supplies on June 2, 2021, with a ceiling value of $32,028.00 and an ultimate completion date of July 2, 2021. Performance occurs in Kent, Washington. The order is priced on a firm fixed price basis for cellular research materials and related supplies supporting the Clinical Center's therapeutic programs.</p>

The NIH Clinical Center awarded a purchase order to Stemcell Technologies Inc. for $10,313.00 on September 6, 2017, with an ultimate completion date of September 5, 2018. No set-aside was used. Performance occurs at Bethesda, Maryland. The order is firm fixed-price and procures biological research products and laboratory supplies—including cell isolation kits, cell culture media, reagents, and specialized scientific equipment—to support biomedical research initiatives at the NIH Clinical...

<p>The NIH Clinical Center awarded a purchase order to Stemcell Technologies Inc. for $17,506 on August 1, 2018, with completion on August 2, 2018. Place of performance is Burien, Washington. The order procures specialized biological research materials and cell isolation or purification products from the vendor's commercial product lines, likely supporting clinical research operations at the National Institutes of Health.</p>

Stemcell Technologies Inc. has been awarded a firm fixed-price purchase order valued at $19,430.40 by the NIH Clinical Center, with an ultimate completion date of December 19, 2026. The contract, which carries no small business set-aside designation, will be performed in Kent, Washington. As a subsidiary of the Canadian biotechnology company Stemcell Technologies, the awardee specializes in providing advanced biological research products and laboratory supplies essential to federal research...